Previous studies have reported significantly decreased CYP4B1 expression in LC tissues [15], identifying it as both a prognostic biomarker and a potential therapeutic target, especially in lung adenocarcinoma [30]. Here, CYP4B1 is linked to lung adenocarcinoma.